Related Experiment Video
Updated: Jul 6, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Interdisciplinary management recommendations for toxicity associated with interferon-alfa therapy
Axel Hauschild1, Katharina C Kähler, Martin Schäfer
1Department of Dermatology, University Clinic Schleswig-Holstein, Campus Kiel, Germany. ahauschild@dermatology.uni-kiel.de
Summary:
Adjuvant interferon-alpha (IFN-alpha) therapy in patients with melanoma has been established as standard therapy since more than 10 years.During IFN-alpha therapy, flu-like symptoms, gastrointestinal disorders, arthralgias and neuropsychiatric symptoms are the most common side effects. The management and prophylaxis of these side effects have been improved by a more detailed understanding of pathophysiologic mechanisms and increased clinical experience. New insights in the relevance of detection of autoantibodies and development of autoimmunity have influenced the clinical pathway substantially. This review covers the pathomechanisms, incidence and optimized therapy of IFN-alpha-associated side effects.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Drug toxicity: Drug–Drug Interaction
Myocarditis IV: Nursing Management
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Drug toxicity: Idiosyncratic Reactions
Therapeutic Drug Monitoring: Affecting Factors